Business Description
Century Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US15673T1007
Description
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.63 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.28 | |||||
| Debt-to-EBITDA | -0.47 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -2.86 | |||||
| Beneish M-Score | -3.52 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -18.1 | |||||
| 3-Year EPS without NRI Growth Rate | -18.5 | |||||
| 3-Year FCF Growth Rate | -12.1 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 86.04 | |||||
| 9-Day RSI | 73.6 | |||||
| 14-Day RSI | 64.82 | |||||
| 6-1 Month Momentum % | -54.28 | |||||
| 12-1 Month Momentum % | -3.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.39 | |||||
| Quick Ratio | 10.39 | |||||
| Cash Ratio | 10 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.2 | |||||
| Shareholder Yield % | -68.34 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -4896.46 | |||||
| Net Margin % | -4837.73 | |||||
| FCF Margin % | -4243.05 | |||||
| ROE % | -64.97 | |||||
| ROA % | -33.97 | |||||
| ROIC % | -66.07 | |||||
| ROC (Joel Greenblatt) % | -136.47 | |||||
| ROCE % | -35.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 37.5 | |||||
| PB Ratio | 0.71 | |||||
| Price-to-Tangible-Book | 0.88 | |||||
| EV-to-EBIT | 0.22 | |||||
| EV-to-EBITDA | 0.25 | |||||
| EV-to-Revenue | -10.7 | |||||
| EV-to-Forward-Revenue | 12.1 | |||||
| EV-to-FCF | 0.25 | |||||
| Price-to-Net-Current-Asset-Value | 10.87 | |||||
| Price-to-Net-Cash | 27.17 | |||||
| Earnings Yield (Greenblatt) % | 454.55 | |||||
| FCF Yield % | -82.2 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IPSC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Century Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.685 | ||
| EPS (TTM) ($) | -1.85 | ||
| Beta | 1.59 | ||
| Volatility % | 162.52 | ||
| 14-Day RSI | 64.82 | ||
| 14-Day ATR ($) | 0.132175 | ||
| 20-Day SMA ($) | 1.325 | ||
| 12-1 Month Momentum % | -3.47 | ||
| 52-Week Range ($) | 1.14 - 5.51 | ||
| Shares Outstanding (Mil) | 85.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Century Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Century Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Century Therapeutics Inc Frequently Asked Questions
What is Century Therapeutics Inc(IPSC)'s stock price today?
The current price of IPSC is $1.63. The 52 week high of IPSC is $5.51 and 52 week low is $1.14.
When is next earnings date of Century Therapeutics Inc(IPSC)?
The next earnings date of Century Therapeutics Inc(IPSC) is 2025-03-14 Est..
Does Century Therapeutics Inc(IPSC) pay dividends? If so, how much?
Century Therapeutics Inc(IPSC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers